Trial of Fibroblast Growth Factor-1 Shows Safety, Suggests Efficacy
A first study in patients of an intranasal-delivered therapy for Parkinson’s disease is now complete, and early findings support the treatment being safe and leading to improvements in motor function, Zhittya Genesis Medical, the therapy’s developer, announced. Zhittya is offering a first look at the trial data via a…